Int. J. Mol. Sci. 2013, 14(6), 11145-11156; doi:10.3390/ijms140611145
Article

Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients

1,* email, 2email, 1email and 3email
Received: 20 February 2013; in revised form: 7 April 2013 / Accepted: 14 May 2013 / Published: 27 May 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The aim of this study was to investigate the prognostic value of tumor markers in operable non-small cell lung cancer (NSCLC) patients. A total of 481 NSCLC patients were enrolled in the present study. High levels of neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125) and squamous cell carcinoma antigen (SCC) were detected in 306 (63.6%), 89 (18.5%) and 125 (26.0%) patients, respectively. Seventy-eight of 481 patients died of disease progression, and the median disease-free survival (DFS) and overall survival (OS) were 16.0 and 21.0 months, respectively. The three-year DFS rate was 56.7%, and the OS rate was 75.3%. For serum NSE, the three-year cumulative DFS rate for the normal and elevated group was 67.7% and 51.8% (p = 0.007). The OS in patients with high and normal levels of NSE was 34.0 months and 48.0 months, respectively. The median DFS was 46.0 months versus 32.0 months (p = 0.001), and the OS was 48.0 months versus 44.0 months (p = 0.001) in patients with normal and high levels of CA125. For patients with squamous cell carcinoma, the overall survival was significantly shorter in patients with elevated levels of SCC (p = 0.041). In the multivariate analysis high levels of NSE, CA125 and clinical stage were significantly correlated with worse prognosis (p < 0.05). Patients with all three tumor markers elevated presented the worst prognosis (p < 0.05). In our analysis, high levels of preoperative serum NSE and CA125 are correlated with worse survival in operable NSCLC patients.
Keywords: tumor marker; CA125; NSE; SCC; lung cancer
PDF Full-text Download PDF Full-Text [786 KB, uploaded 19 June 2014 04:54 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Yu, D.; Du, K.; Liu, T.; Chen, G. Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. Int. J. Mol. Sci. 2013, 14, 11145-11156.

AMA Style

Yu D, Du K, Liu T, Chen G. Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. International Journal of Molecular Sciences. 2013; 14(6):11145-11156.

Chicago/Turabian Style

Yu, Dangfan; Du, Kaiqi; Liu, Taifeng; Chen, Guojun. 2013. "Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients." Int. J. Mol. Sci. 14, no. 6: 11145-11156.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert